L’USAGE DE DROGUES EN FÉDÉRATION WALLONIE-BRUXELLES

134
l’usage de drogues en Fédération Wallonie-bruxelles || rapport 2011-2012
Hall, W., Degenhardt, L., & Linskey, L. (2001). The health and psychological effects of cannabis use. Monograph
Series N°44. Commonwealth of Australia : Canberra.
Hall, W., & Degenhardt, L. (2000). Cannabis use and psychosis : a review of clinical and epidemiological
evidence. Australian and New zealand Journal of Psychiatry, 34, 26-34.
Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Duchin, J. S., & Alexander, E. R. (2001). Sharing of drug
preparation equipment as a risk factor for hepatitis C. American Journal of Public Health, 91, 42-46.
Hahn, J. A., Page-Shafer, K., Lum, P. J., Ochoa, K., & Moss, A. R. (2001). Hepatitis C virus infection and
needle exchange use among young injection drug users in San Francisco. Hepatology, 34, 180-187.
Hedrich, D. (2004). European report on drug consumption rooms. European Monitoring Centre for Drugs and
Drug Addiction : Luxembourg.
Hedrich D, Kerr T, Dubois-Arber F. (2010). Drug consumption facilities in Europe and beyond. In T. Rhodes
& D. Hedrich (Eds.), Harm reduction : evidence, impacts and challenges. Monograph 10. Publications Office of
the European Union : Luxembourg.
Hser, Y. I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotics addicts.
Archives of General Psychiatry, 58, 503-508.
Judd, P. H., Thomas, N., Schwartz, T., Outcalt, A., & Hough, R. (2003). A dual diagnosis demonstration
project : treatment outcomes and cost analysis. Journal of Psychoactive Drugs, 35, 181-192.
Kerr, T., Wood, E., Grafstein, E., Ishida, T., Shannon, K., et al. (2005). High rates of primary care and
emergency department use among injection drug users in Vancouver. Journal of Public Health, 27, 62-66.
Kimber J, Mac Donald M, Van Beek I, Kaldor J, Weatherburn D, et al. (2003). The Sydney medically
supervised injecting centre : Client characteristics and predictors of frequent attendance during the first
12 months of operation. Journal of Drug Issues, 33, 639-648.
Kimber J, Dolan K, Van Beek I, Hedrich D, & zurhold H. (2003). Drug consumption facilities : an Update
since 2000. Drug and Alcohol Review, 22, 227-233.
Lopez, D., Martineau, H., & Palle, C. (2004). Mortalité liée aux drogues illicites : Étude d’une cohorte
rétrospective de personnes interpellées pour usage de stupéfiants. Observatoire Français des Drogues et
Toxicomanies : Saint-Denis.
Lynch, W. J., Roth, M. E., et Caroll, M. E. (2002). Biological basis of sex differences in drug abuse :
preclinical and clinical studies. Psychopharmacology, 164, 121-137.
Macías, J., Palacios, R. B., Claro, E., Vargas, J., Vergara, et al., (2008). High prevalence of hepatitis C virus
infection among noninjecting drug users : association with sharing the inhalation implements of crack.
Liver International, 28, 781-786.
Marshall, B. D. L., Milloy, M. -J., Wood, E., Montaner, J. S. G., & Kerr, T. (2011). Reduction in overdose
mortality after the opening of North America’s first medically supervised safer injecting facility : a
retrospective population-based study, The Lancet, 377, 1429-1437.
Martinez, A. & Talal, A.H. (2008). Noninjection drug use : an under-appreciated risk factor for hepatitis C
virus transmission. Liver International, 28, 757-760.
Matheï, C., Robaeys, G., Van Ranst, M., Van Damme, P., & Buntinx, F. (2005). The epidemiology of hepatitis
C among injecting drug users in Belgium. Acta Gastroenterology Belgica, 68, 50-54.